US surpasses 1,000 measles cases for 1st time in 5 years: CDC
Jan Sonnenmair/Getty Images
(NEW YORK) — The U.S. has surpassed 1,000 measles cases for the first time in five years, according to new data from the Centers for Disease Control and Prevention (CDC) published Friday.
A total of 1,001 cases have been confirmed in 30 states including Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia and Washington.
The last time the U.S. recorded more than 1,000 cases occurred in 2019, when there were 1,274 confirmed infections over the course of a year, CDC data shows.
The CDC says 13% of measles patients in the U.S. this year have been hospitalized, the majority of whom are under age 19.
Among the nationally confirmed cases, CDC says about 96% are among people who are unvaccinated or whose vaccination status is unknown.
Meanwhile, 2% are among those who have received just one dose of the measles, mumps, rubella (MMR) vaccine and 2% are among those who received the required two doses, according to the CDC.
This is a developing story. Please check back for updates.
(NEW YORK) — More than five years after the first cases of COVID-19 were detected in the United States, hundreds of people are still dying every week.
Last month, an average of about 350 people died each week from COVID, according to data from the Centers for Disease Control and Prevention (CDC).
While high, the number of deaths is decreasing and is lower than the peak of 25,974 deaths recorded the week ending Jan. 9, 2021, as well as weekly deaths seen in previous spring months, CDC data shows.
Public health experts told ABC News that although the U.S. is in a much better place than it was a few years ago, COVID is still a threat to high-risk groups.
“The fact that we’re still seeing deaths just means it’s still circulating, and people are still catching it,” Dr. Tony Moody, a professor in the department of pediatrics in the division of infectious diseases at Duke University Medical Center, told ABC News.
The experts said there are a few reasons why people might still be dying from the virus, including low vaccination uptake, waning immunity and not enough people accessing treatments.
Low vaccine uptake, waning immunity
During the 2024-25 season, only 23% of adults aged 18 and older received the updated COVID-19 vaccine as of the week ending April 26, according to CDC data.
Among children, just 13% of them received the updated COVID vaccine over the same period, the data shows.
Dr. Gregory Poland, a vaccinologist and president and co-director of the Atria Research Institute — which focuses on disease prevention — said there are likely not enough people receiving the vaccine, which is contributing to the number of weekly COVID deaths.
However, for those who have received the vaccine, some may not be developing a proper immune response.
“There are some people who may be genetically inclined to not respond well to the vaccine. That’s the topic I have studied with other viral vaccines,” Poland told ABC News. “The more common issue is that people are immunocompromised and can’t respond well.”
Additionally, Poland said that immunity from COVID-19 vaccines wanes over time, increasing the likelihood of being infected.
This is why the current recommendation for those aged 65 and older is to receive two doses of the updated COVID vaccine six months apart.
“Another reason for death due to COVID is being elderly, being what we call immunosenescent, where you do not have the immunologic ability to respond the same way you did in your 30s and 40s,” Poland said. “On top of it, if you do get infected by the time you’re in your 70s, 80s, there is some … accumulating co-morbidity.”
CDC data shows that those aged 75 and older currently have the highest rate of COVID-19 deaths at 4.66 per 100,000.
Not accessing COVID treatments
Currently, there are treatments for COVID-19 patients in the form of antiviral pills, including molnupiravir from Merck and Ridgeback Biotherapeutics and Paxlovid from Pfizer.
Both treatments must be started within five days of COVID symptoms appearing and are given twice daily for five days, with Merck’s being four pills each time and Pfizer’s being three pills each.
There is also remdesivir, an intravenous medication that must be started within seven days of COVID symptoms appearing.
“I do think that we don’t necessarily make use of the tools that we have on hand in the best way possible,” Moody said. “I’ve certainly talked to people who have gotten medications when they got COVID and they made a huge difference. … The trials’ data would definitely suggest that the drugs are effective.”
“I do think that we may not be using the drugs as effectively, or in as many people as it might help,” he continued.
Moody said it’s possible some COVID patients are coming down with symptoms but are not going to the doctor until their symptoms become severe. Alternatively, some people are not undergoing COVID testing when they have symptoms and, therefore, are missing COVID diagnoses.
“I’m sure that there are people who are infected who are not being detected [and not being] treated,” Moody said, but he added that not everyone needs to be tested regularly and that just high-risk people should test more frequently.
(NEW YORK) — Emergency rooms across the country are seeing a spike in tick bite cases, according to new data from the Centers for Disease Control and Prevention.
July has already seen the highest number of tick-related ER visits since 2017, with the Northeast region reporting the most cases, the CDC said.
Young children and elderly adults appear particularly vulnerable, with those under 10 and over 70 years old having the highest rates of emergency room visits, according to the CDC.
For residents in the New York tristate area, the threat is particularly severe. The Fordham Tick Index, which monitors tick activity in southern New York, Connecticut and Northern New Jersey, currently rates the bite risk as “very high” – 9 out of 10 on its scale.
The CDC reports that climate change may be contributing to the increasing numbers. In regions where Lyme disease is already present, milder winters result in fewer disease-carrying ticks dying during cold months, the agency notes.
According to CDC data, May typically marks the annual peak for tick-bite emergencies. These rising numbers have prompted health officials to remind the public about the dangers posed by these tiny insects.
The CDC warns that ticks can transmit various diseases through their bites, many of which share similar symptoms. Most people who visit emergency rooms report fever and chills, headaches, fatigue and muscle aches. Some patients also develop distinctive rashes, particularly those associated with Lyme disease and Rocky Mountain Spotted Fever.
With outdoor activities in full swing this summer, the CDC has issued several recommendations to prevent illness. The agency advises avoiding wooded and brushy areas with high grass and leaf litter, and staying in the center of trails when hiking. It also recommends using Environmental Protection Agency-registered insect repellents containing DEET, Picaridin, or other approved ingredients.
The CDC recommends treating outdoor clothing and gear with permethrin, which remains effective even after multiple washes. Those planning to use both sunscreen and insect repellent should apply sunscreen first, followed by the repellent.
Health officials are also emphasizing that no area is immune to tick activity.
(WASHINGTON) — In a major policy change, the Food and Drug Administration has announced a plan to limit access to future COVID-19 shots only to people over 65 years old or those with an underlying health condition.
This change would apply to any future updated versions of the vaccine, a spokesperson at the department of Health and Human Services told ABC News. For the past several years, COVID shots have been updated ahead of the winter respiratory virus season to better match the evolving virus.
But FDA Commissioner Dr. Martin Makary and FDA vaccine head Dr. Vinay Prasad argued this week that annual booster shots are not worth the risk for otherwise healthy people.
The FDA plans to impose these restrictions on future shots for younger, healthy people, unless vaccine makers are willing to pay for newer and and lengthy placebo-controlled trials.
“We are evaluating the details shared today and discussions with the FDA are ongoing,” Pfizer told ABC News in a statement.
“We appreciate the FDA’s clear guidance and remain committed to working with the Agency to provide the data they need to ensure access for Americans,” Moderna told ABC News.
Since the COVID-19 virus can mutate quickly, a lengthy clinical trial may result in a vaccine that no longer protects against currently circulating variants, experts cautioned.
“By the time you finish the trial, the strain that’s out there in the community is probably long gone. So, they’re basically saying, unless you’re in those higher-risk groups, you can forget about getting the COVID vaccine,” former acting CDC director Richard Besser, now president and CEO of the Robert Wood Johnson Foundation, told ABC News.
A spokesperson for HHS, which oversees FDA, told ABC News, “The COVID-19 public health emergency has officially ended, and we are entering a new phase in our response to the virus. A rubber-stamping approach to approving COVID boosters in perpetuity without updated clinical trial data under the Biden administration is now over.”
Last month, more than 300 people died each week from COVID, according to the latest CDC data. Death rates were even higher earlier this year as the virus was spreading, with nearly 1,000 Americans dying weekly in January.
The new policy comes as the FDA’s vaccine committee of independent advisers are set to meet on Thursday to discuss the latest data on vaccine safety and efficacy, including COVID shots. Typically, FDA leadership waits until after hearing the advice of its advisers before implementing a new approval or policy change.
Previously, updated COVID vaccines had been recommended annually by the CDC for everyone over the age of 6 months. The CDC has historically set vaccine recommendations, while the FDA determines which vaccines to authorize or approve after being deemed safe and effective.
“The FDA has kind of usurped the CDC’s recommending capacity. Usually, the FDA is a regulatory body. They say the vaccine can be sold, and the CDC says, ‘Jere’s the groups who should get it,’” Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia, told ABC News.
Added Besser: “It’s also not something the FDA would normally do. It’s something CDC would do. And so that’s a really important issue here.”
The new COVID vaccine framework would allow an estimated 33% of the U.S. population to be eligible for the shots, or at least 100 million people, FDA officials noted. It matches recommendations from other countries such as the U.K., Canada and Australia.
Experts say there is a real scientific debate about whether annual boosters are necessary for otherwise young and healthy children and younger adults, especially now that most Americans now have some immunity gained from past vaccination and infections.
In mid-April, the CDC’s vaccine committee of independent advisers had discussed whether to keep the recommendation that everyone over 6 months receive an annual COVID vaccine.
Some experts have argued an FDA restriction could create insurmountable barriers for those who no longer qualify but want to get vaccinated anyway to protect vulnerable family members. Officials at the FDA have called for more evidence on whether vaccines prevent transmission before providing that option.
“To date, there is no high-quality evidence that you getting a booster protects your grandma, beyond your grandma getting the booster herself,” Prasad said at an FDA press conference Tuesday. “Does it lead to less transmission? Does it lead to fewer instances of severe disease? Again, we are interested in evidence to inform this claim.”
Insurance coverage of future COVID vaccines will likely be determined based on recommendations from the CDC and the agency’s independent panel of advisers later this summer. A final recommendation on who should be eligible for updated shots will likely come from the CDC director later this year.
Insurance companies will “continue to monitor the forthcoming recommendations and guidance from ACIP and CDC. As of today, there is no change in how plans cover the existing vaccines for the previously recommended populations,” according to AHIP, a national organization representing insurance companies.
“The ultimate goal of the vaccine is to keep people out of the hospital. But people could reasonably say, moderate infections aren’t fun either, so I’m going to choose and get this vaccine,” Offit noted. “I think that’s fine. I think it’s a reasonable choice. I just hope that we’re not restrictive.”
